Home LiteratureArticle Details
PMID: 28795399 Published · ppublish English Journal Article

New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.

Clinical pharmacology and therapeutics ·Vol. 102 ·No. 6 ·2017-12-00 ·Pages 897-902

Relling MV, Krauss RM, Roden DM, Klein TE, Fowler DM, Terada N, Lin L, Riel-Mehan M, Do TP, Kubo M, Yee SW, Johnson GT, Giacomini KM

Abstract

The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies and methodologies to enable discovery. The Pharmacogenomics Research Network (PGRN) has become a community-driven network of investigators spanning scientific and clinical disciplines. Here, we highlight the activities and types of resources that enable PGRN members to enhance and drive basic and translational research in pharmacogenomics.

MeSH Terms
Biomedical Research/organization & administration Humans Pharmacogenetics/organization & administration Precision Medicine/methods Translational Research, Biomedical/organization & administration
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Relling M V
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Krauss R M
Children's Hospital Oakland Research Institute, Oakland, California, USA.
Roden D M
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Klein T E
Department of Biomedical Data Science, Stanford University, Palo Alto, California, USA.
Fowler D M
Department of Genome Sciences, University of Washington, Seattle, Washington, USA. | Department of Bioengineering, University of Washington, Seattle, Washington, USA.
Terada N
Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, USA.
Lin L
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Riel-Mehan M
Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA.
Do T P
Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA.
Kubo M
RIKEN Center for Integrative Medical Science, Yokohama, Japan.
Yee S W
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Johnson G T
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA. | Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA.
Giacomini K M
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA. | Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA.
References (6)
6 references, click to expand
  1. Overview of the BioBank Japan Project: Study design and profile.
    J Epidemiol. 2017 Mar;27(3S):S2-S8 PMID: 28189464
  2. Pharmacogenomics knowledge for personalized medicine.
    Clin Pharmacol Ther. 2012 Oct;92(4):414-7 PMID: 22992668
  3. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
    Clin Pharmacol Ther. 2011 Mar;89(3):464-7 PMID: 21270786
  4. Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
    Clin Pharmacol Ther. 2016 Nov;100(5):423-426 PMID: 27256705
  5. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
    Blood. 2012 Aug 9;120(6):1165-74 PMID: 22730540
  6. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
    Genet Med. 2017 Feb;19(2):215-223 PMID: 27441996
Article Info
Journal
Clinical pharmacology and therapeutics
Abbr.
Clin Pharmacol Ther
ISSN
1532-6535
DOI
10.1002/cpt.755
Published
2017-12-00
Epub
2017-00-10
Pages
897-902
Language
English
Region
United States
NLM ID
0372741
PMCID
PMC5706548
Subset
IM
Grants
NIGMS NIH HHS · R24 GM061374 · United States
NIGMS NIH HHS · P50 GM115318 · United States
NIGMS NIH HHS · R24 GM115264 · United States
NIGMS NIH HHS · R24 GM115277 · United States
NIGMS NIH HHS · U24 GM115370 · United States
NIGMS NIH HHS · R01 GM109110 · United States
NIGMS NIH HHS · R24 GM119977 · United States
NCATS NIH HHS · UL1 TR001427 · United States
NIDDK NIH HHS · UC4 DK104194 · United States
NIDDK NIH HHS · P30 DK098722 · United States
NIGMS NIH HHS · U01 GM061374 · United States
NIGMS NIH HHS · P50 GM115305 · United States
NIGMS NIH HHS · P50 GM115279 · United States
External Links
PubMed source DOI: 10.1002/cpt.755 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2